

# Tolerance and safety study of a new paediatric peptide feed

<b>Submission date</b> 27/01/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 27/01/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 03/07/2009	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Maartje Jansen

**Contact details**  
Numico Research B.V.  
P.O. Box 7005  
Wageningen  
Netherlands  
6700 CA

## Additional identifiers

**Protocol serial number**  
NTR451; 100027

## Study information

**Scientific Title**

**Study objectives**  
Not provided at time of registration

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Received from local medical ethics committee

**Study design**

Multicentre, randomised, single blind, active controlled, crossover trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Paediatric peptide feed

**Interventions**

After baseline measurements, patients receive either their current feed (= control) for 4 weeks followed by 4 weeks paediatric peptide feed, or paediatric peptide feed for 4 weeks followed by 4 weeks on the control feed. After 4 weeks and after 8 weeks, children return to the clinic where the outcome measures are assessed. Children are invited to participate in a 3-month open extension of the study.

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome(s)**

Total score on questionnaire on gastro-intestinal tolerance: diarrhoea, constipation, nausea, vomiting, abdominal distention, flatulence and burping of paediatric peptide feed versus control feeds.

**Key secondary outcome(s))**

1. Stool output (frequency, volume and consistency) of paediatric peptide feed versus control feeds
2. Mean change in weight (kg) of paediatric peptide feed versus control feeds
3. Mean change in growth, expressed as z-scores for weight and height (head circumference for children younger than two years old) of paediatric peptide feed versus control feeds
4. Mean change in triceps skin fold thickness and mid arm circumference of paediatric peptide feed versus control feeds
5. Blood concentrations of serum albumin, haemoglobin, haematocrit and C-reactive protein (CRP) of paediatric peptide feed versus control feeds
6. Convenience/ease of use of paediatric peptide feed versus control feeds
7. Dietary intake of paediatric peptide feed versus control feeds

**Completion date**

01/10/2006

# Eligibility

## Key inclusion criteria

1. Children requiring a paediatric peptide feed. Some conditions where this is required may include inflammatory bowel disease, short bowel syndrome, pancreas/liver disease, chronic diarrhoea, cystic fibrosis, undiagnosed gut problems, coeliac disease.
2. Approximately 8 - 30 kg in weight
3. Peptide based feed prescribed for at least 50% of daily energy requirements
4. Expected need of peptide based feed for a minimum of 2 months
5. Written parental informed consent

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Child

## Sex

All

## Key exclusion criteria

1. Infants under 1 year of age
2. Children receiving parenteral nutrition for more than 50% energy requirements
3. Children with galactosaemia
4. Children with cow milk allergy
5. Children with medical or dietary contraindication
6. If the investigator is, for any reason, uncertain about the willingness to comply with the protocol requirements, the subject can be excluded
7. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
8. Multiple allergies

## Date of first enrolment

01/10/2005

## Date of final enrolment

01/10/2006

# Locations

## Countries of recruitment

Netherlands

## Study participating centre

**Numico Research B.V.**

Wageningen

Netherlands

6700 CA

## **Sponsor information**

### **Organisation**

Numico Research B.V. (Netherlands)

### **ROR**

<https://ror.org/00aj77a24>

## **Funder(s)**

### **Funder type**

Industry

### **Funder Name**

Numico Research B.V. (Netherlands)

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration